NetworkNewsBreaks

ThursdayAug 16, 2018 12:39 pm

NetworkNewsBreaks – Youngevity International, Inc. (NASDAQ: YGYI) Subsidiary Secures $250M Coffee Contract

Leading omni-direct lifestyle company Youngevity International, Inc. (NASDAQ: YGYI) recently announced that its wholly owned subsidiary, CLR Roasters, has entered into a five-year contract for the sale and processing of over 41 million pounds of green coffee on an annual basis. Referencing current coffee prices and futures, the company estimates that this contract will generate revenues in excess of $50 million per annum throughout the five-year term. “We have invested millions of dollars in our coffee operations with our sights on creating value for our business,” Steve Wallach, CEO of Youngevity, stated in the news release. “A contract of this size…

Continue Reading

ThursdayAug 16, 2018 12:12 pm

NetworkNewsBreaks – Auscrete Corp. (ASCK) Offers Unique Path to Affordable Home Ownership

Auscrete (OTC: ASCK) aims to offer turnkey houses for roughly $100 per square foot, which is significantly less than the 2017 median list price of $148 per square foot. A recent article discussing the company reads: “This impressive feat can be accomplished because Auscrete produces hybrid cementitious building products in the form of wall and roof segments that are infused with millions of minuscule air “aggregates” that are evenly distributed throughout the cast sections. This creates a superior, lightweight product, without compromising strength or structural integrity. Each hybrid panel also incorporates a distinctive XPS insulation composition that ensures greater comfort…

Continue Reading

ThursdayAug 16, 2018 12:08 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances Development of HIV Single Agent Therapy

Biotechnology company CytoDyn (OTCQB: CYDY) recently reported significant developmental progress during phase 3 trials for its PRO 140 monotherapy for human immunodeficiency virus (HIV) after observing enhanced response rates at higher doses of the treatment (http://nnw.fm/3g2Np). An article discussing the company’s progress reads: “The dosage increase will apply to all newly enrolled patients but also to current trial participants who failed to maintain suppressed HIV viral load on a lower dose. Approximately 70 percent of trial participants who started PRO 140 at 525 mg and have been undergoing treatment between one and nine months are achieving HIV viral load suppression,…

Continue Reading

ThursdayAug 16, 2018 11:32 am

NetworkNewsBreaks – Patriot One Technologies Inc. (TSX.V: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) Secures Technology Funding through Agreement with International Defense Contractor

Patriot One Technologies Inc. (TSX.V: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) recently announced that it has reached an agreement in principle with a major international defense contractor. Per the terms of the agreement, Patriot One will receive funding toward the development and integration of its PATSCAN CMR technology, subject to certain governmental approvals. The purpose of the agreement is to extend the technical development of Patriot One’s cognitive microwave radar technology, surpassing the initial goals of the company. This will be comprised of a two stage, several million dollar non-dilutive funding for the development of the PATSCAN CMR technology to include…

Continue Reading

ThursdayAug 16, 2018 9:57 am

NetworkNewsBreaks – Zenergy Brands, Inc. (ZNGY) Reports Q2 Financial Results

Next-generation energy and technology company Zenergy Brands (OTC: ZNGY) this morning announced that it has filed its Form 10-Q with the SEC, reporting financials from the second quarter of 2018. The company reported total revenue of $464,404 during the second quarter of 2018, demonstrating an increase of 54% when compared to the total revenue of $301,809 from the previous quarter. Zenergy attributes the revenue growth primarily to the company’s retail electricity services, and energy conservation and efficiency contracts. The company also reported an increase in growth profit of 17% from the previous quarter, totaling $109,315 for Q2. Zenergy’s Zero Cost…

Continue Reading

ThursdayAug 16, 2018 9:26 am

NetworkNewsBreaks – FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) Unveils New FANbassador Program

Fan-focused entertainment company FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) this morning unveiled its new FANbassador Program. The company is giving users and fans of its FANDOM SPORTS app the chance to become contributing writers on the app for a week. Interested users can submit their best sports fights to [email protected]. The top three fights with the best headlines and pictures will win a chance to become a paid FANbassador writer for a week. In the future, the company intends to give official FANbassadors a chance to pick a fight and talk trash on the FANDOM SPORTS…

Continue Reading

WednesdayAug 15, 2018 2:30 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Continues to Demonstrate Versatility

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is the developer of a disruptive drug delivery platform, DehydraTECH™, that the company out-licenses to entities aiming to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. An article discussing the company’s technology reads: “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has applied for one more to the USPTO. This is because, in lab studies, the proprietary technology has shown evidence of transporting active pharmaceutical ingredients (APIs) across…

Continue Reading

WednesdayAug 15, 2018 2:22 pm

NetworkNewsBreaks –The Flowr Corp. Secures Sales License from Health Canada

The Flowr Corp., a cultivator of premium cannabis in Canada, recently announced that it has received its sales license from Health Canada enabling the company to sell to the Canadian medical and adult-use recreational markets. Initially, Flowr will offer two brands: FlowrRx and Flowr. FlowrRx is a premium quality medicinal cannabis that empowers patients to live improved, fuller lives. The company’s premium recreational adult-use brand, Flowr, will serve the recreational market when it opens in October. “We’re pleased to have successfully completed the rigorous Health Canada sales licensing process and are excited to begin offering consumers and patients the high-quality…

Continue Reading

WednesdayAug 15, 2018 12:13 pm

NetworkNewsBreaks – Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) and WeedMD Inc. (TSX-V: WMD) (OTC: WDDMF) (FSE: 4WE) Ink Definitive JV Agreement to Develop Cannabis Beverages Inc.

Phivida Holdings (CSE: VIDA) (OTCQX: PHVAF), together with WeedMD (TSX-V: WMD) (OTC: WDDMF) (FSE: 4WE), this morning announced that the companies have signed a final definitive Joint Venture (“JV”) agreement to develop and operate Cannabis Beverages Inc. (“CanBev”). The strategic partnership positions CanBev as an early mover in the cannabis-infused beverage market, with each company retaining 50% each of the Class A shares in the new company. CanBev’s Board of Directors will be comprised of five individuals, two nominated by each company and one independent director. The partners have agreed to fund capital requirements of CanBev equally, beginning with initial…

Continue Reading

WednesdayAug 15, 2018 11:25 am

NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Inks Licensing Agreement with Asterion Cannabis; Engages Monster Media to Provide IR Services

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed an agreement with Asterion Cannabis Inc. to acquire a worldwide license to use, manufacture, distribute and sell three Health Canada approved natural health products. Per the terms of the licensing agreement, Asterion has granted PreveCeutical a non-exclusive license to use Asterion's intellectual property to make or have made, use, distribute, sell, offer to sell and promote the products in exchange for a royalty fee payable to Asterion equaling 20% of the gross sales. The licensing agreement’s initial term is five years and…

Continue Reading